Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204
29 septembra, 2020 8:31 pmMeeting: 2017 ASCO Annual Meeting Track: Melanoma/Skin Cancers Abstract number: 9507 Citation: J Clin Oncol 35, 2017...
Combined Checkpoint Inhibition Ushers in a New Era of CNS Therapy in Melanoma
29 septembra, 2020 8:31 pmJune 4, 2017 Data from two phase II studies, the CheckMate 204 trial and the Anti-PD1 Brain Collaboration (ABC)...
KONGRES ASCO 2017 PRINIESOL ŠTYRI HLAVNÉ KLINICKY KRITICKÉ SPRÁVY V LIEČBE MALÍGNEHO MELANÓMU
29 septembra, 2020 8:31 pm1. Boli publikované dlhodobé výsledky trojročného celkového prežívania pacientov v rámci štúdie Keynote-006. Predbežné výsledky štúdie Keynote-006, ktorá porovnávala ipilimumab (blokátor...
Phase II study of maintenance pembrolizumab (pembro) in extensive stage small cell lung cancer (ES-SCLC) patients (pts)
29 septembra, 2020 8:31 pmMeeting: 2017 ASCO Annual Meeting Track: Lung Cancer – Non-small Cell Local-Regional/Small Cell/Other Thoracic Cancer Abstract number: 8504...
Efficacy of the Addition of Cisplatin to Single-Agent First-Line Chemotherapy in Elderly Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Joint Analysis of the Multicenter, Randomized Phase III MILES-3 and MILES-4 studies
29 septembra, 2020 8:31 pmMeeting: 2017 ASCO Annual Meeting Track: Lung Cancer – Non-small Cell Metastatic Abstract number: 9002 Citation: J...
Alectinib Versus Crizotinib in Treatment-Naive Advanced ALK Positive Non-Small Cell Lung Cancer (NSCLC): Primary Results of the Global Phase III ALEX Study
29 septembra, 2020 8:31 pmMeeting: 2017 ASCO Annual Meeting Track: Lung Cancer – Non-small Cell Metastatic Abstract number: LBA 9008 Citation:...
First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G
29 septembra, 2020 8:31 pmMeeting: 2017 ASCO Annual Meeting Track: Lung Cancer – Non-small Cell Metastatic Abstract number: 9094 Citation: J...
Nivolumab (N) plus ipilimumab (I) as first-line (1L) treatment for advanced (adv) NSCLC: 2-yr OS and long-term outcomes from CheckMate 012
29 septembra, 2020 8:31 pmMeeting: 2017 ASCO Annual Meeting Track: Lung Cancer – Non-small Cell Metastatic Abstract number: 9093 Citation: J...
Response to salvage chemotherapy following exposure to immune checkpoint inhibitors in patients with non-small cell lung cancer
29 septembra, 2020 8:31 pmMeeting: 2017 ASCO Annual Meeting Track: Lung Cancer – Non-small Cell Metastatic Abstract number: 9084 Citation: J...
Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC)
29 septembra, 2020 8:31 pmMeeting: 2017 ASCO Annual Meeting Track: Lung Cancer – Non-small Cell Metastatic Abstract number: 8509 Citation: J...